Dupixent is used to treat certain cases of: Dupixent comes as a single-dose prefilled syringe and a single-dose prefilled pen. You may receive your Dupixent injections at your doctor’s office.

Dupixent comes in a prefilled syringe or prefilled pen for injection under the skin. Dupixent is used to treat the following in certain situations: Dupixent contains the active ingredient dupilumab.

For people with COPD, Dupixent is given via subcutaneous injections, at a recommended dose of 300 mg, once every other week. It is available as a single-dose prefilled syringe or prefilled pen ...

Injection Pen Market. The global injection pen market is on track for substantial growth, with a forecasted compound annual ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for certain inflammatory conditions. Dupixent has interactions with some other drugs. Examples include certain ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The US Food and Drug Administration (FDA) has accepted for review the resubmitted supplemental Biologics License Application (sBLA) for Sanofi and Regeneron’s Dupixent (dupilumab) in chronic ...

(REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental biologics license application or sBLA for Dupixent (dupilumab ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic spontaneous urticaria, an inflammatory skin disease. The FDA has accepted the ...